^
Association details:
| Biomarker: | BCR-ABL1 F317V |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations
Excerpt:
In contrast to imatinib mesylate, mutations recovered in the presence of 50 nM nilotinib were limited to L248V, p-loop (G250E, Y253H, E255K), T315I, F359C, L384M, and L387F. One novel mutation (E292V) was seen in a single clone at 50 nM.
DOI:
10.1182/blood-2006-02-004580
